Platelet-active drugs: The relationships among dose, effectiveness, and side effects - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest

Volumn 126, Issue 3 SUPPL., 2004, Pages 234S-264S

  Patrono, Carlo ^a   Coller, Barry ^b   FitzGerald, Garret A ^b   Hirsh, Jack ^b   Roth, Gerald ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

Aspirin; Clopidogrel; Efficacy; Platelet active drugs; Side effects

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; HEPARIN; IBUPROFEN; INDOBUFEN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORBOFIBAN; PLACEBO; ROFECOXIB; SIBRAFIBAN; SULFINPYRAZONE; THIENO[3,2 C]PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; UNINDEXED DRUG; WARFARIN; XEMILOFIBAN;

ACUTE HEART INFARCTION; ANIMAL MODEL; ASPIRIN RESISTANCE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DEEP VEIN THROMBOSIS; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATORY CELL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUTROPENIA; NONHUMAN; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 4644289299     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3_suppl.234S     Document Type: Conference Paper

References (317)

1. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119:39S-63S
2. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136:157-160
3. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346:1468-1474
4. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update; consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106:388-391
5. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-assessing ultegra) multicenter study. Circulation 2001; 103:2572-2578
6. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252:233-238
7. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913
8. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235
9. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655
10. Sane DC, McKee SA, Malinin AI, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90:893-895
11. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787
12. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107:32-37
13. Neubauer H, Günesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003; 24:1744-1749
14. Hamm CW, Bertrand M, Braunvald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001; 358:1533-1538
15. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915-1924
16. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189-198
17. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
18. Steinhubl SR, Berger PB, Tift Mann J III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420
19. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442
20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959
21. Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a reappraisal. Arthritis Rheum 2003; 48:12-20
22. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324:71-86
23. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a participate fraction protein. J Clin Invest 1975; 56:624-632
24. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72:3073-3077
25. Burch JW, Stanford PW, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1979; 61:314-319
26. Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72:1521-1525
27. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271:33157-33160
28. 2 synthase. Nat Struct Biol 1995; 2:637-643
29. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96:1109-1116
30. 2 after low-dose aspirin. N Engl J Med 1981; 304:76-79
31. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-1372
32. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71:678-688
33. Weksler BB, Pert SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308:800-805
34. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72:1177-1184
35. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294
36. 2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325:1137-1141
37. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96:272-277
38. Topper JN, Cai J, Falb D, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996; 93:10417-10422
39. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388:678-682
40. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 1984; 311:1206-1211
41. McAdam B, Keimowitz RM, Maher M, et al. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. J Pharmacol Exp Ther 1996; 277:559-564
42. Deniers LM, Budin R, Shaikh B. The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med 1980; 163:24-29
43. Burch JW, Baenziger NL, Stanford N, et al. Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci U S A 1978; 75:5181-5184
44. Burch JW, Majerus PW. The role of prostaglandins in platelet function. Semin Hematol 1979; 16:196-207
45. Cerskus AL, Ali M, Davies BJ, et al. Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo. Thromb Res 1980; 18:389-397
46. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968; 1:779-783
47. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830
48. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340:1421-1425
49. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338:1345-1491
50. Lindblad B, Persson NH, Takolander R, et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24:1125-1128
51. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13
52. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thrombo-embolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ 1980; 280:514-517
53. Harris WH, Athanasoulis CA, Waltman AC, et al. High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. J Bone Joint Surg Am 1982; 64:63-66
54. Harris WH, Athanasoulis CA, Waltman AC, et al. Prophylaxis of deep vein thrombosis after total hip replacement: dextran and external compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg 1985; 67:57-62
55. Farrel B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054
56. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
57. Taylor DW, Barnett HJM, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy; a randomised controlled trial. Lancet 1999; 353:2179-2184
58. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983; 309:396-403
59. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111
60. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313:1369-1375
61. Lorenz RL, Weber M, Kotzur J, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation, Lancet 1984; 1:1261-1264
62. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration cooperative study. Circulation 1988; 77:1324-1332
63. Brown BG, Cukingnan RA, DeRouen T, et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 1985; 72:138-146
64. Turpie AGG, Gent G, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993; 329:524-529
65. Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72:127-129
66. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51:1537-1541
67. Dale J, Myhre E, Storstein O, et al. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94:101-111
68. Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301:577-579
69. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
70. Bousser MG, Eschwege E, Haugenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14:5-14
71. Canadian Cooperative Study Group A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299:53-59
72. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8:301-314
73. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349:1569-1581
74. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349:1641-1649
75. Roth GJ, Calverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood 1994; 83:885-898
76. Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682-1687
77. Hanson SR, Harker LA, Bjoinssorl TD. Effect of platelet-modifying drugs on arterial thromboembolism in baboons; aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985; 75:1591-1599
78. Harker LA, Fuster V. Pharmacology of platelet inhibitors. J Am Coll Cardiol 1986; 8:21B-32B
79. Buchanan MR, Rischke JA, Hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res 1982; 25:363-373
80. Gaspari F, Viganò G, Grisio S, et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclo-oxygenase inhibition. J Clin Invest 1987; 79:1788-1797
81. Ratnatunga CP, Edmondson SF, Rees GM, et al. High-close aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992; 85:1077-1082
82. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250:154-161
83. Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296:525-529
84. Green D, Davies RO, Holmes GI, et al. Fibrinolytic activity after administration of diflunisal and aspirin: a double-blind, randomized, placebo-controlled clinical trial. Haemostasis 1983; 13:394-398
85. Quick AJ, Cleasceri L. Influence of acetylsalicylic acid and salicylamide on the coagulation of blood. J Pharmacol Exp Ther 1960; 128:95-99
86. Loew D, Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors. Haemostasis 1976; 5:239-249
87. Kessels H, Beguin S, Andreee H, et al. Measurement of thrombin generation in whole blood: the effect of heparin and aspirin. Thromb Haemost 1994; 72:78-83
88. Szczeklik A, Krzanowski M, Gora P, et al. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80:2006-2011
89. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983; 22:4672-4675
90. Picot D, Loll PJ, Garavito M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367:243-249
91. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1969; 219:68-69
92. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia, Arterioscler Thromb Vasc Biol 1996; 16:948-954
93. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325:445-453
94. Barnett HJM, Kaste M, Meldrum H, et al. Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts. Stroke 1996; 27:588-592
95. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135
96. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979
97. López-Farré A, Caramelo C, Esteban A, et al. Effects of aspirin on platelet-neutrophil interactions; role of nitric oxide and endothelin-1. Circulation 1995; 91:2080-2088
98. Santos MT, Vallès J, Aznar J, et al. Prothrombotic effects of erythrocytes on platelet reactivity; reduction by aspirin. Circulation 1997; 95:63-68
99. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97:350-355
100. Podhaisky HP, Abate A, Polte T, et al. Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E. FEBS Lett 1997; 417:349-351
101. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97:716-720
102. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1:1710-1713
103. Helgason CM, Hoff JA, Kondos GT, et al. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993; 24:1458-1461
104. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24:345-350
105. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke, Stroke 1994; 25:2331-2336
106. Weksler BB, Kent JL, Rudolph D, et al. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985; 16:5-9
107. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78:1003-1007
108. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11:221-227
109. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991; 12:428-433
110. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder: a pilot-study including 180 post-stroke patients. Thromb Res 1993; 71:397-403
111. Bornstein NM, Karepov VG, Aronovich BD, et al. Failure of aspirin treatment after stroke. Stroke 1994; 25:275-277
112. Chamorro A, Escolar G, Revilla M, et al. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. J Neurol Sci 1999; 171:110-114
113. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Haemost 1990; 16:1-20
114. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99:7634-7639
115. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102:1007-1013
116. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001; 345:1809-1817
117. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:573-574
118. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108:1191-1195
119. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965
120. Van Kooten F, Ciabattoni G, Patrono C, et al. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994; 25:278-281
121. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296:313-316
122. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762
123. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998; 351:233-241
124. Collaborative Group of the Primary Prevention Project (PPP), Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357:89-95
125. Special report: preliminary report of the stroke prevention in atrial fibrillation study, N Engl J Med 1990; 322:863-868
126. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539
127. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511
128. Petersen P, Boysan G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; 1:175-179
129. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262
130. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154:1443-1448
131. Stroke Prevention in Atrial Fibrillation Investigators, Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-638
132. Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke 1994; 25:1337-1341
133. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279:1273-1277
134. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low close aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295-1302
135. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308:235-243
136. Mohr DN, Silverstein MD, Murtaugh PA, et al. Prophylactic agents for venous thrombosis in elective hip surgery. Arch Intern Med 1993; 253:2221-2228
137. Callus AS, Salzman EW, Hirsh J, et al. Prevention of venous thrombo-embolism. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Basic principles and clinical practice. Philadelphia, PA: JB Lippincott, 1994; 1331-1345
138. Cruickshank MK, Levine MN, Hirsh J, et al. An evaluation of impedance plethysmography and I-125-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989; 62:830-834
139. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intensive post-operative warfarin and aspirin therapy in the prevention of venous thrombo-embolism after surgery for fractured hip. Arch Intern Med 1989; 149:771-774
140. Graor RA, Steward JH, Lotke PA, et al. RD Heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery [abstract]. Chest 1992; 102(suppl):118S
141. Gent M, Hirsh J, Ginsberg J, et al. The low molecular weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism following surgery for hip fracture. Circulation 1996; 93:80-84
142. Sors H, Meyer G. Place of aspirin in prophylaxis of venous thromboembolism. Lancet 2000; 355:1288-1289
143. Imperiale TF, Stollenwerk-Petrulis A. A meta-analysis of low dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 1991; 266:260-264
144. Uzan S, Beaufils M, Breart G, et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991; 337:1427-1431
145. Italian Study of Aspirin in Pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet 1993; 341:396-400
146. Sibai BM, Caritis SN, Thorn E, et al. Prevention of pre-eclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993; 329:1213-1218
147. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9,364 pregnant women. Lancet 1994; 343:619-629
148. Estudo Colaborativo para Prevencào da Pré-eclampsia com Aspirina Collaborative Group. ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high-risk pregnant women. Br J Obstet Gynaecol 1996; 103:39-47
149. Rotchell YE, Cruickshank JK, Phillips-Gay M, et al. Barbados Low dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105:286-292
150. Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy: the Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol 1998; 105:293-299
151. Caritis S, Sibai B, Hautli J, et al. Low-close aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998; 338:701-705
152. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001; 322:329-333
153. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials, Br J Clin Pharmacol 1993; 35:219-226
154. García Rodríguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33-39
155. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding, BMJ 1995; 310:827-830
156. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications; systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52:563-571
157. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899
158. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413-1416
159. De Abajo FJ, García Rodríguez LA, Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1:1
160. Yeomans ND, Tulassay Z, Juhàsz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 388:719-726
161. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 338:727-734
162. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-973
163. Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30:1764-1771
164. Menè P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995; 15:244-252
165. Pierucci A, Simonetti BM, Pecci G, et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 1989; 320:421-425
166. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419-425
167. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients; Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35:1801-1807
168. Zanchetti A, Hansson L, Leonetti G, et al. Low-dose aspirin does not interefere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002; 20:1015-1022
169. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037-1043
170. FitzGerald GA, Patrono C. Antiplatelet drugs. In; Verstraete M, Fuster V, Topol E, eds. Cardiovascular thrombosis-thrombocardiology, thromboneurology, Philadelphia, PA: Lippincott-Raven, 1998; 121-139
171. Patrono C, Ciabattoni G, Pugliese F, et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77:590-594
172. Reilly IAG, FitzGerald GA, Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs, Blood 1987; 69:180-186
173. García Rodríguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11:382-387
174. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drag use and acute myocardial infarction, Arch Intern Med 2002; 162:1099-1104
175. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359:118-123
176. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162:1105-1110
177. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162:1111-1115
178. Pedersen AK, FitzGerald GA. Cyclooxygenase inhibition, platelet function and drag metabolite formation during chronic administration of sulfinpyrazone in man. Clin Pharmacol Ther 1985; 37:36-42
179. 2 production in patients with myocardial infarction. Eur J Clin Pharmacol 1990; 39:99-100
180. Davì G, Patrono C, Catalane I, et al. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 1993; 13:1346-1349
181. Rajah SM, Rees M, Walker D, et al. Effects of antiplatelet therapy with
182. SINBA Group, Indobufen versus aspirin plus dipyridamole after coronary artery surgery. Coron Artery Dis 1991; 2:897-906
183. Fornaro G, Rossi P, Mantica P, et al. Indobufen in the prevention of thrombo-embolic complications in patients with heart disease. Circulation 1993; 87:162-164
184. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28:1015-1021
185. Bergamasco B, Benna P, Carolei A, et al. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study): Ticlopidine Indobufen Stroke Study. Funct Neurol 1997; 12:33-43
186. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993; 14:951-957
187. Ramis J, Torrent J, Mis R, et al. Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Ther Toxicol 1990; 28:344-349
188. Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, et al. randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J. 2000; 21:457-465
189. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34:840-848
190. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory-drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255
191. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528
192. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288
193. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89:425-430
194. FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316:1247-1257
195. Müller TH, Su CAPF, Weisenberger H, et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30:179-186
196. Diener HC, Darius H, Bertrand-Hardy JM, et al. European Stroke Prevention Study 2: cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55:162-163
197. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100:1667-1672
198. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel, Thromb Haemost 2000; 84:891-896
199. Ding Z, Kini S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues Cys17 and Cys270. Blood 2003; 101:3908-3914
200. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature 2001; 409:202-207
201. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA, 2003; 100:1978-1983
202. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82:17-26
203. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 2:1215-1220
204. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321:501-507
205. Scrutinio D, Cimminiello C Marubini E, et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37:1259-1265
206. Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications, Angiology 1988; 39:802-811
207. Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double blind trial. J Lab Clin Med 1989; 114:84-91
208. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine; results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227:301-308
209. Limet R, David JL, Magotteaux P, et al. Prevention of aortocoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rate of venous coronary bypass grafts; a double-blind study. J Thorac Cardiovasc Surg 1987; 94:773-783
210. FitzGerald GA. Ticlopidine in unstable angina: a more expensive aspirin? Circulation 1990; 82:296-298
211. Yeh SP, Hsueh EJ, Wu H, et al. Ticlopidine-associated aplastic anemia: a case report and review of literature. Ann Hematol 1998; 76:87-90
212. Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524-2528
213. Herbert JM, Bernat A, Samama M, et al. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost 1996; 76:94-98
214. Lecompte TP, Lecrubier C, Bouloux C, et al. Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers. Clin Appl Thromb Hemost 1997; 3:245-250
215. Leon MB, Bairn DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. N Engl J Med 1998; 339:1665-1671
216. More RS, Chauhan A. Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet 1997; 349:146-147
217. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidorel after stenting. J Am Coll Cardiol 2002; 39:9-14
218. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting: EPISTENT Investigators; Evaluation of Platelet IIb/IIIa Inhibitor for Stenting JAMA 1999; 281:806-810
219. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11:180-198
220. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348:1329-1339
221. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30:1288-1295
222. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31:53-59
223. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Haemost 1999; 25:15-19
224. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atrovastatin versus other statin therapies. Am J Cardiol 2003; 92:285-288
225. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel -atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108:921-924
226. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773-1777
227. Bertrand ME, Rupprecht H-J, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629
228. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99:1467-1471
229. Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999; 82:326-336
230. Schwarz M, Nordt T, Bode C, et al. The GPIIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphasM-beta2). Thromb Res 2002; 107:121-128
231. Anderson KM, Weisman HF, Coller BS. Platelet glycoprotein IIb/IIIa receptor inhibitors. In: Hennekens CH, Buring JE, Manson JE, eds. Clinical trials in cardiovascular disease. Philadelphia, PA: WB Saunders, 1999; 166-183
232. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet 1999; 353:227-231
233. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100:437-444
234. Nurden AT, Poujol C, Durrieu-Jais C, et al. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999; 19:2835-2840
235. Coller BS, Peerschke EL, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72:325-338
236. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90:1757-1764
237. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of a short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97:1680-1688
238. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961
239. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet 1994; 343:881-886
240. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696
241. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 1999; 100:2466-2468
242. Peter K, Kohler B, Straub A, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000; 102:1490-1496
243. Nakada MT, Sassoli PM, Tam SH, et al. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates. J Thromb Thrombolysis 2002; 14:15-24
244. Quinn M, Deering A, Stewart M, et al. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99:2231-2238
245. Lev EI, Osende JI, Richard MF, et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol 2001; 37:847-855
246. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay (RPFA): an automated and quantitative cartridge-based method. Circulation 1999; 99:620-625
247. Neumann FJ, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37:1323-1328
248. Kereiakes DJ, Mueller M, Howard W, et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999; 7:265-276
249. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999; 100:1977-1982
250. Mukherjee D, Moliterno DJ. Applications of anti-platelet monitoring in catheterization laboratory. J Thromb Thrombolysis 2000; 9:293-301
251. Kereiakes DJ, Essel JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78:1161-1163
252. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy. Circulation 1997; 95:809-813
253. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitori. Am Heart J 1999; 138:317-326
254. Curtis BR, Swyerr J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99:2054-2059
255. Kaluski E, Leitman M, Khiger I, et al. Delayed thrombocytopenia following abciximab therapy. Int J Cardiovasc Intervent 2001; 4:151-155
256. Shanna S, Bhambi B, Nyitray W, et al. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther 2002; 7:21-24
257. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104:870-875
258. Madan M, Kereiakes DJ, Hermiller JB, et al. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol 2000; 85:435-440
259. Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146:345-350
260. Reverter JC, Bèguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996; 98:863-874
261. Hartman GD, Egbertson MS, Halczenko W, et al. Non-peptide fibrinogen receptor antagonists: I. Discovery and design of exosite inhibitors. J Med Chem 1992; 35:4640-4642
262. Egbertson MS, Chang CT, Duggan ME, et al. Non-peptide fibrinogen receptor antagonists: II. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994; 37:2537-2551
263. Vickers S, Theoharides AD, Arison B, et al. In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos 1999; 27:1360-1366
264. Tirofiban [package insert]. Whitehouse Station, NJ: Merck, 2002
265. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56:377-388
266. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88:1512-1517
267. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high-risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27:536-542
268. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999; 84:391-395
269. Simon DI, Liu CB, Ganz P, et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 2001; 52:425-432
270. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial; Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106:1470-1476
271. Smith BS, Gandhi PJ. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 2001; 11:39-48
272. Januzzi JL Jr, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002; 105:2361-2366
273. Bednar B, Cook JJ, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999; 94:587-599
274. Bougie DW, Wilker FR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100:2071-2076
275. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268:1060-1073
276. Lele M, Sajid M, Wajih N, et al. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001; 104:582-587
277. 2+ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96:1488-1494
278. Alton KB, Kosoglou T, Baker S, et al. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998; 20:307-323
279. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003; 91:17-21
280. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001; 104:406-411
281. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80:11B-20B
282. Li YF, Spencer FA, Becker RC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alpbaIIb/beta3) receptor-directed platelet inhibition. Am Heart J 2001; 142:204-210
283. Tcheng JE, Harrington RA, Kottke Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995; 91:2151-2157
284. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349:1422-1428
285. Harrington RA, Kleiman NS, Kottke Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous intervention. Am J Cardiol 1995; 76:1222-1227
286. Tardiff BE, Jennings LK, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001; 104:399-405
287. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443
288. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037-2044
289. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285:2468-2473
290. Rezkalla SH, Haves JJ, Curtis BR, et al., Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 2003; 58:76-79
291. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453
292. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-1435
293. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87-92
294. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113:1-6
295. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-906
296. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894
297. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study. Lancet 2002; 360:355-360
298. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study [abstract]. Circulation 1996; 94:1-553
299. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497
300. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505
301. Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002; 105:316-321
302. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104:2767-2771.
303. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial: the TIMI 14 Investigators. Circulation 1999; 99:2720-2732
304. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-1914
305. Lincoff AM, Califf RM, Van de Werf F et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduce-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288:2130-2135
306. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96:76-81
307. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000; 342:1316-1324
308. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102:149-156
309. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000; 355:337-345
310. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001; 103:1727-1733
311. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108:399-406
312. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103:201-206
313. Leebeek FWG, Boersma E, Cannon CP, et al. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J 2002; 23:444-457
314. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood 1998; 92:3240-3249
315. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes J Am Coll Cardiol 2000; 36:1514-1519
316. Holmes MB, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 2000; 85:491-493
317. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998; 97:5-9